Sponsors & Exhibitors 2023
Presidential Sponsors
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with
combined strengths in pharmaceuticals and diagnostics. Roche is the world’s
largest biotech company, with truly differentiated medicines in oncology,
immunology, infectious diseases, ophthalmology and neuroscience. Roche is also
the world leader in in vitro diagnostics and tissue-based cancer diagnostics,
and a frontrunner in diabetes management. Roche’s personalised healthcare
strategy aims at providing medicines and diagnostics that enable tangible
improvements in the health, quality of life and survival of patients.
At AbbVie, we set our sights on a future
where vision lasts a lifetime. With a legacy of 75 years in eye care, we’re
proud to offer 125 eye care products that help to preserve and protect vision
for patients around the world. We treat conditions from the front to the back
of the eye, including glaucoma, ocular surface disease and retinal diseases.
Platinum Sponsors
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and
development of novel treatments for retinal diseases with significant unmet
medical needs. The Company is committed to having a positive impact on
patients’ lives by delivering high-quality, safe and effective treatments
designed to address debilitating retinal diseases including earlier stages of
age-related macular degeneration. For more information on the Company, please
visit www.ivericbio.com.
Bayer is a global enterprise with core competencies in the life science
fields of health care and nutrition. Its products and services are designed to
benefit people by supporting efforts to overcome the major challenges presented
by a growing and aging global population. Our vision of helping patients with exudative retinal
disease see a better life is central to how we shape the future of
ophthalmology through extensive research, global collaboration and needs-led
innovation and technology.
Gold Sponsor
Apellis is a global
biopharmaceutical company leveraging courageous science, creativity, and
compassion to deliver life-changing medicines. At Apellis, we are committed to
developing transformative therapies for people living with Geographic Atrophy
(GA) by regulating complement, a part of the body’s immune system. Our work is rooted centrally at C3,
which is the only target in the complement cascade that addresses all three
pathways that can drive disease. Targeting C3 has broad platform potential to
treat many diseases such as GA, where there are currently no treatment options
available. Company details Apellis Switzerland GmbH, Zählerweg 10, 6300 Zug, Switzerland Email: medinfo@apellis.com Websites: www.apellis.com; www.geographicatrophy.eu
Contributors
Heidelberg
Engineering GmbH
Max-Jarecki-Str. 8
69115 Heidelberg
GERMANY
Phone: +49 6221 6463 0
Fax: +49 6221 6463 340
Email: information@heidelbergengineering.com
URL: www.heidelbergengineering.com
Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. The growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions (PACS), electronic medical records (EMR) and large-scale data analysis.
Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop
and launch ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal indications, including
wet AMD, DME and BRVO. The U.S. Food and Drug Administration accepted Outlook
Therapeutics’ Biologics License Application (BLA) for ONS-5010 to treat wet AMD
on October 27, 2022. The FDA set a Prescription Drug User Fee Act (PDUFA) goal
date of August 29, 2023. If ONS-5010 is approved, Outlook Therapeutics expects
to commercialize it as the first and only FDA-approved ophthalmic formulation
of bevacizumab for use in treating retinal diseases in the United States,
United Kingdom, Europe, Japan, Greater China and other markets. Outlook
Therapeutics’ BLA submission for ONS-5010 is as a new BLA under the PHSA 351(a)
regulatory pathway. If ONS-5010 is approved, the Company expects to commercialize it through
best-in-class partnerships. To date, Outlook Therapeutics has manufacturing
partnerships with Fujifilm Diosynth Biotechnologies and Ajinomoto Biopharma
Services to provide product manufacturing in their best-in-class cGMP global
manufacturing facilities. Outlook Therapeutics has also executed a supply agreement for a best-in-class
pre-filled ophthalmic syringe that will provide both ease-of-use for clinicians
and add to ONS-5010’s potential safety profile over the current unapproved
therapies that have caused problems related to syringe malfunction,
contamination, etc. Outlook Therapeutics intends to create goodwill and acceptance among payors, retinal
specialists and patients by offering excellent value in an FDA-approved
ONS-5010.
For
more information, please visit www.outlooktherapeutics.com.
REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.
Wisepress.com,
Europe’s leading conference bookseller, attend around 200 conferences every
year. We have an extensive range of books and journals relevant to the themes
of this conference available at our booth. We also have a comprehensive range
of STM titles available on our online bookshop. Follow us on Twitter
@WisepressBooks.
